CYP1A1 and prostate carcinoma: Similarly, in our study, we found that the CYP1A1 GA + GG genotypes were associated with prostate cancer risk (OR, 1.27; 95% CI, 1.02–1.59) (Table 4), and this evidence of an association was observed not only in the high HAA intake group (OR, 2.86; 95% CI, 1.83–4.47), but also in even the low (OR, 2.05; 95% CI, 1.19–3.63) and moderate (OR, 1.72; 95% CI, 1.07–2.76) HAA intake groups (Table 5).